Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.55 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9214256 | 0.82 | ENPP2 (0.69) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL9214261 | 0.82 | ENPP2 (0.69) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL157163 | 0.78 | KDM4E (0.56) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL397161 | 0.78 | ENPP2 (0.55) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL24598773 | 0.77 | ENPP2 (0.62) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL31047371 | 0.77 | ENPP2 (0.62) | ENPP2TTRKDM4EALDH1A1MGLL | |
| Hydrochloric Acid SCHEMBL3969100 | 0.77 | KDM4E (0.54) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL29155031 | 0.77 | ENPP2 (0.53) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL29155126 | 0.77 | ENPP2 (0.53) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL789866 | 0.75 | ENPP2 (0.70) | ENPP2KDM4EALDH1A1MGLLCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118056820-A | 2, 4-Disubstituted thiophene compound and preparation method and application thereof | 沈阳药科大学 | 2024-05-21 | — | — | CN | disclosed |
| EP-2681205-B1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | UNIV SAARLAND (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-20140057953-A1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140012005-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | DIVERCHIM (FR) | 2014-01-09 | — | — | US | disclosed |
| EP-2681205-A1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | Universität des Saarlandes (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2012117097-A1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | Universität des Saarlandes (DE) | 2012-09-07 | — | — | WO | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2260017-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ENPP2 350/4885TTR 3698/4885KDM4E 2559/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | ENPP2 1252/4885TTR 1812/4885KDM4E 3449/4885 |
| US-20140012005-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | BCAT1, DNPEP, BCAT2 | ENPP2 2671/4885TTR 53/4885KDM4E 3029/4885 |
| US-20140057953-A1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | HSD17B2, HSD17B1, HSD3B2 | ENPP2 793/4885TTR 4516/4885KDM4E 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.